Skip to main content
← DISPATCHES
[WORLD]

The Evolution of CRISPR: Companies Targeting the Epigenome for Disease Therapy

As CRISPR technology advances, companies are now exploring epigenome modifications, opening new avenues for treating various diseases.

Editorial Staff · 2026-06-26 · 1 MIN READ
The Evolution of CRISPR: Companies Targeting the Epigenome for Disease Therapy

CRISPR technology is undergoing significant evolution, moving beyond traditional gene editing techniques.

A number of companies are now focusing on modifying the epigenome, which could have implications for a wide range of diseases.

This shift in focus highlights the potential of CRISPR to not only edit genes but also to influence gene expression through epigenetic changes.